106612-94-6

Basic information

• Product Name: H-HIS-ALA-GLU-GLY-THR-PHE-THR-SER-ASP-VAL-SER-SER-TYR-LEU-GLU-GLY-GLN-ALA-ALA-LYS-GLU-PHE-ILE-ALA-TRP-LEU-VAL-LYS-GLY-ARG-GLY-OH
• Synonyms: Insulinotropin (human);Peptide GLP-1 (human glucose-lowering peptide-1);Glp-I (7-37);Glucagon like peptide I (7-37);Glucagon-related peptide (oncorhynchus kisutch), 3-L-glutamic acid-6-L-phenylalanine-9-L-aspartic acid-12-L-serine-15-L-glutamic acid-16-glycine-21-L-isoleucine-24-L-alanine-27-L-valine-28-L-lysine-31-glycine-;Tglp-1;GLP-1, 7-37;Preproglucagon 78-108
• CAS NO: 106612-94-6
• Molecular Formula: C151H228N40O47
• Molecular Weight: 3355.67
• Product Categories: peptide;peptides pharm
• Mol File: 106612-94-6.mol
• Article Data: 0

Chemical Properties

• Appearance: /
• Density: 1.48±0.1 g/cm3(Predicted)
• Storage Temp.: −20°C
• Water Solubility: Soluble in water at 2mg/ml
• CAS DataBase Reference: H-HIS-ALA-GLU-GLY-THR-PHE-THR-SER-ASP-VAL-SER-SER-TYR-LEU-GLU-GLY-GLN-ALA-ALA-LYS-GLU-PHE-ILE-ALA-TRP-LEU-VAL-LYS-GLY-ARG-GLY-OH(CAS DataBase Reference)
• NIST Chemistry Reference: H-HIS-ALA-GLU-GLY-THR-PHE-THR-SER-ASP-VAL-SER-SER-TYR-LEU-GLU-GLY-GLN-ALA-ALA-LYS-GLU-PHE-ILE-ALA-TRP-LEU-VAL-LYS-GLY-ARG-GLY-OH(106612-94-6)
• EPA Substance Registry System: H-HIS-ALA-GLU-GLY-THR-PHE-THR-SER-ASP-VAL-SER-SER-TYR-LEU-GLU-GLY-GLN-ALA-ALA-LYS-GLU-PHE-ILE-ALA-TRP-LEU-VAL-LYS-GLY-ARG-GLY-OH(106612-94-6)

Safety Data

• Safety Statements: 22-24/25
• WGK Germany: 3
• Hazardous Substances Data: 106612-94-6(Hazardous Substances Data)

Usage

Uses

Glucagon-Like Peptide 1 Fragment 7-37 human has been used:as a positive control for insulin secretion of pancreatic isletsto test its effect on insulin response in horse isletsin combination with mesenchymal stem cells (MSCs) test its protective effects in myocardial infarction

General Description

Glucagon-Like Peptide 1 Fragment 7-37 human (GLP-1-(7-37)) is an amino-truncated form of GLP-1.

Biochem/physiol Actions

Glucagon-Like Peptide 1 Fragment 7-37 human (GLP-1-(7-37)) interacts with the GLP-1 receptor (GLP-1r). It mediates insulin release by stimulating the cyclic AMP accumulation in islet cells GLP-l(7-37) is a potential therapeutic agent due to its insulin-secretagogue functionality.